Published in Blood Weekly, April 28th, 2005
"We are extremely enthusiastic about this study, which represents the first use of an allogeneic adult stem cell to treat the consequences of heart attack in humans. The trial design is supported by an extensive series of preclinical studies performed in animal models that demonstrate that MSCs safely and effectively reduce the damage caused by heart attack," said lead investigator Dr. Joshua Hare, director of Heart Failure and Cardiac Transplantation and the Cardiobiology Section of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.